The Koebner Phenomenon May Contribute to the Development of Calciphylaxis: a Case Series

The Koebner Phenomenon May Contribute to the Development of Calciphylaxis: a Case Series

University of Massachusetts Medical School eScholarship@UMMS Open Access Publications by UMMS Authors 2021-04-28 The Koebner phenomenon may contribute to the development of calciphylaxis: A case series Colleen K. Gabel Massachusetts General Hospital Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Dermatology Commons, Nutritional and Metabolic Diseases Commons, Pathological Conditions, Signs and Symptoms Commons, and the Skin and Connective Tissue Diseases Commons Repository Citation Gabel CK, Chakrala T, Dobry AS, Garza-Mayers AC, Ko LN, Nguyen ED, Shah R, St. John J, Nigwekar SU, Kroshinsky D. (2021). The Koebner phenomenon may contribute to the development of calciphylaxis: A case series. Open Access Publications by UMMS Authors. https://doi.org/10.1016/j.jdcr.2021.04.016. Retrieved from https://escholarship.umassmed.edu/oapubs/4692 Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. CASE SERIES The Koebner phenomenon may contribute to the development of calciphylaxis: A case series Colleen K. Gabel, BS,a Teja Chakrala, BS,a AllisonS.Dobry,MD,b Anna Cristina Garza-Mayers, MD, PhD,c Lauren N. Ko, MD, MEd,c Emily D. Nguyen, MD,a Radhika Shah, MD, PharmD,d Jessica St. John, MD, MBA, MPH,e Sagar U. Nigwekar, MD, MMSc,f and Daniela Kroshinsky, MD, MPHa Boston and Worcester, Massachusetts; Irvine, California; and New Brunswick, New Jersey. Key words: calciphylaxis; Koebner phenomenon; Koebnerization; pathogenesis; risk factors; trauma. INTRODUCTION Abbreviation used: Calciphylaxis is characterized by calcific occlu- sion of vessels and subsequent tissue ischemia due to IQR: interquartile range thrombosis.1,2 The precise pathogenetic mechanism behind calciphylaxis remains unclear. In the original experiment by Hans Selye and colleagues,3-7 soft- METHODS tissue calcification was induced in rats by applying a A retrospective chart review was performed sensitizing agent, followed by a ‘‘challenger’’ agent of patients with a diagnosis of calciphylaxis at after a specific time period. Trauma may represent Massachusetts General Hospital and Brigham and one of these ‘‘challenger’’ agents, serving as an Women’s Hospital between January 2006 and inducer of endothelial dysfunction and subsequent December 2018. Patients with calciphylaxis were thrombosis, leading from tissue calcification to identified from the Partners Research Patient Data calciphylaxis. Registry, an electronic medical record database, us- Koebnerization, a term used to describe the ing the diagnosis code International Classification of appearance of isomorphic lesions in areas of Diagnosis, Tenth Revision (ICD-10) E83.59 and ICD-9 trauma,8 has been postulated to be a feature of 275.49, and a word search for ‘‘calciphylaxis’’ in the calciphylaxis.9 This hypothesis arose from reports of hospital discharge and/or outpatient clinic notes. patients who developed calciphylaxis following mild Each record was examined to determine whether skin trauma, such as that caused by chronic resting of the clinical findings and/or biopsy supported a elbows on thighs, placement of ice packs, and diagnosis of calciphylaxis, recorded either by a injections involving various medications such as dermatologist or a nephrologist with expertise in iron dextran, tobramycin, and especially insulin.10,11 calciphylaxis. In total, 145 patients with calciphylaxis Rigorous studies demonstrating the relationship were identified. Chart review was conducted of the between calciphylaxis and Koebnerization and an initial consultation with dermatology as well as underlying mechanism are limited. To better under- progress notes to assess the presence of calciphylaxis stand this association, this study retrospectively lesions in sites of prior trauma. Patients were included identified characteristics of patients who presented if clinical documentation stated that a lesion had with calciphylaxis in areas of trauma, suggesting the appeared in a site of trauma. Twenty-two patients presence of Koebnerization. meeting this definition were identified. The study was From the Department of Dermatology, Massachusetts General Correspondence to: Daniela Kroshinsky, MD, MPH, Department of Hospital, Bostona; Department of Dermatology, University of Dermatology, Massachusetts General Hospital, 50 Staniford California, Irvine School of Medicineb; Department of Derma- Street, 2nd Floor, Boston, MA 02114. E-mail: dkroshinsky@ tology, Harvard Medical School, Bostonc; Department of partners.org. Dermatology, Robert Wood Johnson Medical School, New JAAD Case Reports 2021;13:57-61. Brunswickd; Department of Dermatology, University of Massa- 2352-5126 chusetts Medical School, Worcestere; and Department of Ó 2021 by the American Academy of Dermatology, Inc. Published Nephrology, Massachusetts General Hospital, Boston.f by Elsevier, Inc. This is an open access article under the CC BY- Funding sources: None. NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ IRB approval status: Reviewed and approved by Partners Health 4.0/). Institutional Review Board (approval no.: 2008P001589). https://doi.org/10.1016/j.jdcr.2021.04.016 57 58 Gabel et al JAAD CASE REPORTS JULY 2021 approved by the Partners Health Institutional Review Table I. Patient characteristics in a cohort of Board (approval number: 2008P001589). calciphylaxis patients From each patient’s chart, age at presentation, Characteristic Total (n = 22) sex, race, and comorbidities before presentation Demographics were abstracted. Warfarin exposure was Age at diagnosis (y), median (IQR) 62.0 (53.5-65.5) defined by continuous use of warfarin for at least Female, n (%) 11 (50.0) 6 months before development of calciphylaxis. Race, n (%) Thromboembolic events were defined as deep Caucasian 17 (77.3) venous thrombosis or pulmonary embolism. Each Black or African American 1 (4.5) chart was also reviewed to record the date of onset Asian 1 (4.5) of calciphylaxis, the date of diagnosis, and the Unknown 3 (13.6) circumstances around development of lesions in Ethnicity, n (%) sites of trauma, if applicable. All patients were Hispanic or Latino 1 (4.5) followed for at least 1 year. Categorical variables Not Hispanic or Latino 14 (63.6) are reported as percentages, and continuous vari- Unknown 7 (31.8) Comorbidities, n (%) ables as medians and interquartile ranges (IQR). Kidney function Normal 2 (9.1) RESULTS Stage 1 0 (0.0) Baseline characteristics Stage 2 1 (4.5) Table I summarizes the patient characteristics. Stage 3 3 (13.6) The incidence of calciphylaxis lesions appearing in Stage 4 1 (4.5) sites of trauma in this cohort was 22/145 (15.2%). ESRD 15 (68.2) The median age at diagnosis was 62.0 years (IQR, Diabetes 18 (81.8) 53.5-65.5 years). There were 11 female patients, Obese 11 (50.0) comprising 50.0% of the study population; 17 pa- Hyperparathyroidism 8 (36.4) tients (77.3%) were Caucasian, and 1 patient (4.5%) Autoimmune disease 3 (13.6) Malignancy (past or current) 2 (9.1) was Hispanic or Latino. Thromboembolic events 1 (4.5) Among the patients studied, 20 (90.9%) had Medications, n (%) chronic kidney disease and 15 (68.2%) had end- Vitamin D 11 (50.0) stage renal disease. Other comorbidities included Warfarin 7 (31.8) diabetes (81.8%), obesity (50.0%), hyperparathyroid- Systemic corticosteroids 5 (22.7) ism (36.4%), autoimmune diseases (systemic lupus erythematosus or antiphospholipid antibody syn- ESRD, End-stage renal disease; IQR, interquartile range. drome) (13.6%), past or current malignancy (9.1%), and thromboembolic events (4.5%). Prior medica- trauma, including insulin injections (3 patients), tion use included vitamin D (50.0%), warfarin surgical interventions (3 patients), biopsy site (1 (31.8%), and systemic corticosteroids (22.7%). One patient), catheter placement (1 patient), and removal patient (4.5%) was receiving nonwarfarin anticoagu- of peritoneal dialysis catheter (1 patient). The details lation treatment at the time of calciphylaxis diag- of patients who had surgical interventions are as nosis. The median number of years on dialysis at the follows: In 1 patient, active calciphylaxis developed time of diagnosis was 3.0 (IQR, 0.5-4.0). after surgical debridement of a chronic sacral decu- bitus ulcer previously not affected by calciphylaxis; Development of Koebner phenomenon in 1 patient, calciphylaxis developed in a sternotomy The circumstances in which calciphylaxis devel- wound after a coronary artery bypass graft; and in 1 oped in patients were evaluated (Table II). In 1 patient, calciphylaxis developed in previously unin- patient, Koebnerization developed twice, and these volved areas of the lower extremity after a below- incidents are listed twice in the table. In 14 patients the-knee amputation. The patient who underwent a (60.9%), calciphylaxis lesions appeared in sites of biopsy had multiple other lesions, which remained noniatrogenic accidental trauma. These inciting stable in the immediate and longitudinal periproce- events included hitting a body part on an object dural time frame, whereas the affected lesion had (wheelchair, dishwasher) (4 patients), abrasion (3 drastic expansion of purpura, which subsequently patients), mechanical

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    6 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us